Publications
Detailed Information
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Cited 75 time in
Web of Science
Cited 73 time in Scopus
- Authors
- Issue Date
- 2019-06-04
- Publisher
- BioMed Central
- Citation
- Cardiovascular Diabetology. 18(1):71
- Keywords
- Residual cardiovascular risk ; Visceral obesity ; Diabetes ; Atherogenic dyslipidemia ; Triglycerides ; Remnant cholesterol ; Selective peroxisome proliferator-activated receptor alpha modulator ; SPPARMalpha ; Pemafbrate (K-877) ; Infammation ; PROMINENT
- Abstract
- In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
- ISSN
- 1475-2840
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.